FY2024 EPS Estimates for Eyenovia Increased by HC Wainwright

Eyenovia, Inc. (NASDAQ:EYEN) – Research analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Eyenovia in a report released on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.51) for the year, up from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.56 EPS.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period last year, the firm posted ($0.18) EPS.

Separately, William Blair raised shares of Eyenovia to a “strong-buy” rating in a research note on Friday, August 30th.

Eyenovia Stock Performance

Eyenovia stock opened at $0.34 on Friday. The company’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $0.71. Eyenovia has a fifty-two week low of $0.33 and a fifty-two week high of $2.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27.

Insider Activity

In other news, CEO Michael M. Rowe bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was acquired at an average cost of $0.57 per share, with a total value of $28,500.00. Following the completion of the purchase, the chief executive officer now owns 82,927 shares of the company’s stock, valued at $47,268.39. This represents a 151.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 7.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Eyenovia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eyenovia in the second quarter valued at about $26,000. Ground Swell Capital LLC bought a new position in shares of Eyenovia during the 2nd quarter worth approximately $27,000. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Eyenovia by 24.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares in the last quarter. Financial Management Network Inc. acquired a new position in shares of Eyenovia during the third quarter worth approximately $39,000. Finally, SkyView Investment Advisors LLC acquired a new position in shares of Eyenovia during the second quarter worth approximately $87,000. 25.84% of the stock is owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.